Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Obesity (Silver Spring). 2020 Nov;28(11):2064-2072. doi: 10.1002/oby.22969. Epub 2020 Oct 6.
Antidepressant medications are the first-line treatment option for moderate to severe major depressive disorder. However, most antidepressants have numerous documented adverse events, including cardiometabolic effects and weight gain, which are major public health concerns. Antidepressant agents provide varying risk of associated weight gain, including significant within-class differences. Some agents, such as mirtazapine, show significant levels of weight gain, while others, such as bupropion, demonstrate weight-loss effects. Current findings suggest the role of histamine and serotonin off-target appetite-promoting pathways in adverse weight-gain effects. Therefore, controlling for undesired weight effects is an important consideration for the selection of antidepressants.
抗抑郁药物是治疗中重度重性抑郁障碍的首选治疗方案。然而,大多数抗抑郁药都有许多已记录的不良事件,包括对心血管代谢的影响和体重增加,这是主要的公共卫生关注点。抗抑郁药会带来不同程度的体重增加风险,包括同一类药物之间也存在显著差异。一些药物,如米氮平,会导致明显的体重增加,而另一些药物,如安非他酮,则会产生体重减轻的效果。目前的研究结果表明,组胺和血清素的非靶点食欲促进途径在不良体重增加效应中起作用。因此,控制不必要的体重效应是选择抗抑郁药时需要考虑的一个重要因素。